Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia? Journal Article

Authors: Bewersdorf, J. P.; Stahl, M.; Zeidan, A. M.
Article Title: Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Abstract: The 5-year overall survival rate of AML patients remains 25-40%. The prognosis is even more dismal for older patients who are ineligible for intensive chemotherapy and patients with secondary or relapsed/refractory AML. In 2017, 4 new drugs were approved by the US Food and Drug Administration for AML treatment: The FLT3 inhibitor midostaurin, the isocitrate dehydrogenase (IDH)-2 inhibitor enasidenib, a liposomal formulation of cytarabine and daunorubicin (CPX-351), and the anti-CD33 antibody gemtuzumab ozogamicin. Additionally, the IDH1 inhibitor ivosidenib has received FDA approval in July 2018. However, all these drugs were approved in certain settings and/or for certain subsets of AML patients. Herein, we review the mechanisms of actions and preclinical data, highlight pivotal clinical trial data, and discuss future directions and challenges for further development of these 5 novel therapeutics. Finally, we briefly overview some of the highly promising agents that are currently in advanced stages of clinical development.
Keywords: novel therapies; inhibitor; targeted therapy; acute myelogenous leukemia; epigenetic therapy; future directions
Journal Title: Leukemia and Lymphoma
Volume: 60
Issue: 6
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2019-06-01
Start Page: 1354
End Page: 1369
Language: English
DOI: 10.1080/10428194.2018.1546854
PUBMED: 30652518
PROVIDER: scopus
Notes: Source: Scopus
Citation Impact
MSK Authors
  1. Maximilian Stahl
    15 Stahl